| Accession |
PRJCA011385 |
| Title |
A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) |
| Relevance |
Medical |
| Data types |
biomaker PD-L1; TMB
|
| Organisms |
Homo sapiens
|
| Description |
Nivolumab, ipilimumab, and platinum doublet chemotherapy each have non-overlapping anti-cancer mechanisms and may have synergistic and/or added activity as combination therapy. As previously demonstrated in phase 1 trial CA209012, ipilimumab enhanced nivolumab's anti-cancer activity. Adding ipilimumab to nivolumab and platinum doublet chemotherapy will likely further enhance the overall clinical activity of nivolumab plus platinum doublet chemotherapy and prevent progression/disease-related death. Two cycles of chemotherapy added during induction may be helpful to control initial disease symptoms and tumor growth quickly and maybe sufficient to provide a synergistic effect with nivolumab and ipilimumab by increasing tumor antigen and reducing inhibitory signal with a net effect of activating the host immune system. |
| Sample scope |
Multiisolate |
| Release date |
2022-08-23 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Bristol-Myers Squibb (China) Investment Co., Ltd., Bristol-Myers Squibb Company
|
|
2018L02287/2018L02286
|
|
|
|
| Submitter |
zhao
nan (1165095416@qq.com)
|
| Organization |
Jilin Cancer Hospital |
| Submission date |
2022-08-23 |
